0001606498-24-000055.txt : 20240502 0001606498-24-000055.hdr.sgml : 20240502 20240502070913 ACCESSION NUMBER: 0001606498-24-000055 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240502 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVANOS MEDICAL, INC. CENTRAL INDEX KEY: 0001606498 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 464987888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36440 FILM NUMBER: 24905242 BUSINESS ADDRESS: STREET 1: 5405 WINDWARD PARKWAY STREET 2: SUITE 100 SOUTH CITY: ALPHARETTA STATE: GA ZIP: 30004 BUSINESS PHONE: 844-428-2667 MAIL ADDRESS: STREET 1: 5405 WINDWARD PARKWAY STREET 2: SUITE 100 SOUTH CITY: ALPHARETTA STATE: GA ZIP: 30004 FORMER COMPANY: FORMER CONFORMED NAME: Avanos Medical, Inc. DATE OF NAME CHANGE: 20180702 FORMER COMPANY: FORMER CONFORMED NAME: Halyard Health, Inc. DATE OF NAME CHANGE: 20140424 8-K 1 avns-20240502.htm 8-K avns-20240502
0001606498falseMay 2, 202400016064982024-05-022024-05-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: May 2, 2024
(Date of earliest event reported)
avanoslogo.jpg
AVANOS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware001-36440 46-4987888
(State or other jurisdiction of incorporation)(Commission file number)(I.R.S. Employer Identification No.)
5405 Windward Parkway
Suite 100 South
Alpharetta,Georgia30004
(Address of principal executive offices)(Zip code)
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common Stock - $0.01 Par ValueAVNSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 2.02            Results of Operations and Financial Condition
On May 2, 2024, Avanos Medical, Inc. (the "Company") issued a press release announcing its results of operations for the three months ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report or Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01        Financial Statements and Exhibits
(d)Exhibits.
Exhibit No.Description
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    
AVANOS MEDICAL, INC.
Date: May 02, 2024By:/s/ Mojirade James
Mojirade James
Senior Vice President and General Counsel


 EX-99.1 2 avns1q2024form8kex991.htm EX-99.1 Document

avanoslogo.jpg
Investor Contact: Michael Greiner
Avanos Medical, Inc.
470-562-2692
Investor.Relations@Avanos.com
Media Contact: Katrine Kubis
Avanos Medical, Inc.
CorporateCommunications@Avanos.com

Avanos Medical, Inc. Announces First Quarter 2024 Results
ALPHARETTA, Ga., May 2, 2024/PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2024 financial results.
“As we begin the second year of our three-year transformation initiative, we are pleased with our first quarter results,” said Joe Woody, Avanos’s chief executive officer. Woody added, “We continue to make progress on our long-term margin expansion targets, are delivering on our Digestive Health growth objectives and have made improvements in our Pain Management and Recovery franchise that will support our mid-single digit growth in the back half of the year.”
First Quarter 2024 Financial Highlights
•Total net sales from continuing operations were $166.1 million, a 4.3% increase from the comparable prior year period.
•Net income from continuing operations for the quarter was $0.5 million, compared to net loss from continuing operations of $7.8 million a year ago.
•Adjusted net income from continuing operations totaled $10.1 million, compared to $6.0 million a year ago.
•Diluted earnings per share from continuing operations was $0.01, compared to diluted loss per share of $0.17 a year ago.
•Adjusted diluted earnings per share from continuing operations was $0.22, compared to $0.13 a year ago.
•Adjusted EBITDA was $21.6 million, compared to $16.1 million a year ago.
First Quarter 2024 Operating Results From Continuing Operations
For the three months ended March 31, 2024, net sales totaled $166.1 million, an increase of 4.3% compared to the prior year period, primarily from strong demand and volume in our Digestive Health portfolio, primarily from our NeoMed neonatal and pediatric feeding solutions, as well as overall favorable volume in our Pain Management and Recovery portfolio, primarily driven by Game Ready and Diros. This was partially offset by slightly unfavorable pricing for our Pain Management and Recovery products.
Gross margin during the first quarter of 2024 was 57.1%, compared to 57.4% in the prior year period. Adjusted gross margin was 59.8% compared to 59.6% last year. Gross profit margin decreased primarily due to costs related to our Transformation Process priorities and plant separation costs associated with the divestiture of our respiratory health (“RH”) business, partially offset by favorable volume and product mix.


Selling and general expenses as a percentage of net sales was 50.3% for the first quarter of 2024, compared to 55.7% for the first quarter of 2023. On an adjusted basis, selling and general expenses as a percentage of net sales was 45.8% for the first quarter of 2024, compared to 48.0% for the first quarter of 2023. Selling and general expenses decreased primarily due to savings realized from the execution on our Transformation Process and a reduction in external spending.
Operating profit was $4.0 million, compared to operating loss of $6.1 million in the prior year period, primarily due to higher sales volume along with a decrease in selling and general expenses related to the execution on the Transformation Process and restructuring priorities. On an adjusted basis, operating profit totaled $16.3 million, compared to $11.2 million a year ago.
Adjusted EBITDA from continuing operations was $21.6 million in the three months ended March 31, 2024, compared to $16.1 million in the three months ended March 31, 2023.
Cash Flow and Balance Sheet
Cash from operations less capital expenditures, or free cash flow, for the first quarter was an outflow of $12.1 million, driven primarily by cash used in operating activities, compared to an outflow of $10.8 million a year ago. The Company’s cash balance at March 31, 2024 was $75.8 million, compared to $87.7 million at year-end 2023.
Total debt outstanding, net of unamortized discounts, was $176.6 million at March 31, 2024, compared to $168.0 million at December 31, 2023.
Discontinued Operations
Net sales from discontinued operations were $16.9 million in the three months ended March 31, 2024, compared to $32.4 million in the three months ended March 31, 2023.
2024 Outlook
For the year, the Company anticipates revenue between $685 million and $705 million from continuing operations, adjusted gross margins between 59.5% and 60.5% and adjusted diluted earnings per share from continuing operations of between $1.30 and $1.45 for the year.
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:
•Adjusted net income
•Adjusted diluted earnings per share
•Adjusted gross and operating profit
•Adjusted effective tax rate
•Adjusted EBITDA
•Free cash flow
These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:
•Certain acquisition and integration charges related to acquisitions.
•Expenses associated with restructuring and transformation activities, including the divestiture of the Company’s RH business in the fourth quarter of 2023.
•Expenses associated with European Union Medical Device Regulation (“EU MDR”) compliance.


•The amortization of intangible assets associated with prior business acquisitions.
•The tax effects of certain adjusting items.
•The benefit associated with the tax effects of the CARES Act.
•The positive or negative effect of changes in currency exchange rates during the year.
The Company provides these non-GAAP financial measures as supplemental information to its GAAP financial measures. Management and the Company’s board of directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating profit, adjusted EBITDA, and free cash flow to: (a) evaluate the Company’s historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the Company’s business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of the Company’s ongoing business operations.
Additionally, the compensation committee of the Company’s board of directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the Company’s net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.
Our competitors may define these non-GAAP financial measures differently, and as a result, our measure of these non-GAAP financial measures may not be directly comparable to those of other companies. Items excluded from these non-GAAP financial measures are significant components in understanding and assessing financial performance. These non-GAAP financial measures are supplemental measures of operating performance that do not represent, and should not be considered in isolation or as an alternative to, or substitute for, the financial statement data presented in the Company’s consolidated financial statements as indicators of financial performance. These non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of the Company’s results as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP financial measures as supplemental information.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.
Conference Call Webcast
Avanos Medical, Inc. will host a conference call today at 9 a.m. ET. The conference call can be accessed live over the internet at https://avanos.investorroom.com or via telephone by dialing 800-836-8184 in the United States. A replay of the call will be available at noon ET today by calling 888-660-6345 in the United States and entering passcode 99423#. A webcast of the call will also be archived in the Investors section on the Avanos website.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today’s most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
Forward-Looking Statements
This press release contains information that includes or is based on “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue” and similar expressions. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and


uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; shortage in drugs used in our Surgical Pain and Recovery products or other disruptions in our supply chain; the ongoing regional conflicts between Russia and Ukraine and in the Middle East; our ability to successfully execute on or achieve the expected benefits of our transformation initiative or our divestiture, acquisition or merger transactions; inflationary pressures; financial conditions affecting the banking system and the potential threats to the solvency of commercial banks; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. The information contained herein speaks only as of the date of this release and we undertake no obligation to update forward-looking statements, except as may be required by the securities laws.
Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-Q.


AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)
(in millions, except per share amounts)
Three Months Ended March 31,
20242023
Net Sales$166.1 $159.3 
Cost of products sold71.3 67.9 
Gross Profit94.8 91.4 
Research and development expenses7.0 7.5 
Selling and general expenses83.6 88.8 
Other expense, net0.2 1.2 
Operating Income (Loss)
4.0 (6.1)
Interest income0.6 0.5 
Interest expense(3.1)(3.5)
Income (Loss) Before Income Taxes1.5 (9.1)
Income tax (provision) benefit
(1.0)1.3 
Income (Loss) from Continuing Operations0.5 (7.8)
(Loss) Income from discontinued operations, net of tax(1.4)7.3 
Net Loss$(0.9)$(0.5)
Interest expense, net$2.5 $3.0 
Income tax benefit
0.5 0.1 
Depreciation and amortization11.4 12.1 
EBITDA$13.5 $14.7 
Earnings (Loss) Per Share
Basic
Continuing operations$0.01 $(0.17)
Discontinued operations(0.03)0.16 
Basic Loss Per Share$(0.02)$(0.01)
Diluted
Continuing operations$0.01 $(0.17)
Discontinued operations(0.03)0.16 
Diluted Loss Per Share$(0.02)$(0.01)
Common Shares Outstanding
Basic46.2 46.6 
Diluted46.7 46.6 




AVANOS MEDICAL, INC.
Discontinued Operations Summary
(unaudited)
(in millions, except per share amounts)
Three Months Ended March 31,
20242023
Net Sales$16.9 $32.4 
Cost of products sold15.9 19.3 
Gross Profit1.0 13.1 
Research and development expenses— 0.4 
Selling, general and other expenses— 3.9
Other expense, net2.9 0.1 
Operating (Loss) Income(1.9)8.7 
(Loss) Income from discontinued operations before income taxes(1.9)8.7 
Income tax benefit (provision) from discontinued operations0.5 (1.4)
(Loss) Income from discontinued operations, net of tax$(1.4)$7.3 
(Loss) Earnings Per Share
       Basic$(0.03)$0.16 
Diluted$(0.03)$0.16 


AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)

Gross Profit
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Continuing
Operations		Discontinued
Operations		TotalContinuing
Operations		Discontinued
Operations		Total
As reported$94.8 $1.0 $95.8 $91.4 $13.1 $104.5 
Restructuring and transformation charges0.7 — 0.7 — — — 
Post-RH Divestiture transition charges0.5 — 0.5 — — — 
Intangibles amortization3.4 — 3.4 3.6 — 3.6 
As adjusted non-GAAP$99.4 $1.0 $100.4 $95.0 $13.1 $108.1 
Gross profit margin, as reported57.1 %5.9 %52.3 %57.4 %40.4 %54.5 %
Gross profit margin, as adjusted59.8 %5.9 %54.9 %59.6 %40.4 %56.4 %


AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)

Operating Profit (Loss)
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Continuing
Operations		Discontinued
Operations		TotalContinuing
Operations		Discontinued
Operations		Total
As reported$4.0 $(1.9)$2.1 $(6.1)$8.7 $2.6 
Acquisition and integration-related charges0.3 — 0.3 1.5 — 1.5 
Restructuring and transformation charges(a)
2.9 — 2.9 8.9 — 8.9 
Post-RH Divestiture transition charges1.0 — 1.0 — — — 
Post-RH Divestiture restructuring0.7 — 0.7 — — — 
EU MDR Compliance(b)
1.3 — 1.3 1.1 — 1.1 
Intangibles amortization6.1 — 6.1 5.8 0.5 6.3 
As adjusted non-GAAP$16.3 $(1.9)$14.4 $11.2 $9.2 $20.4 
__________________________________________________
(a) Expenses incurred for the Transformation Process are included in “Costs of products sold,” “Research and development” and “Selling and general expenses” on the Condensed Consolidated Income Statements.
(b) In the three months ended March 31, 2024, EU MDR Compliance related charges are included in “Selling and general expenses” on the Condensed Consolidated Income Statements. In the three months ended March 31, 2023, EU MDR Compliance related charges are included in “Selling and general expenses” on the Condensed Consolidated Income Statements.


AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)

Income (Loss) Before Taxes
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Continuing
Operations		Discontinued
Operations		TotalContinuing
Operations		Discontinued
Operations		Total
As reported$1.5 $(1.9)$(0.4)$(9.1)$8.7 $(0.4)
Acquisition and integration-related charges0.3 — 0.3 1.5 — 1.5 
Restructuring and transformation charges2.9 — 2.9 8.9 — 8.9 
Post-RH Divestiture transition charges1.0 — 1.0 — — — 
Post-RH Divestiture restructuring0.7 — 0.7 — — — 
EU MDR Compliance1.3 — 1.3 1.1 — 1.1 
Intangibles amortization6.1 — 6.1 5.8 0.5 6.3 
As adjusted non-GAAP$13.8 $(1.9)$11.9 $8.2 $9.2 $17.4 





AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)

Tax (Provision) Benefit
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Continuing
Operations		Discontinued
Operations		TotalContinuing
Operations		Discontinued
Operations		Total
As reported$(1.0)$0.5 $(0.5)$1.3 $(1.4)$(0.1)
Tax effects of adjusting items(2.7)— (2.7)(3.5)(1.1)(4.6)
As adjusted non-GAAP$(3.7)$0.5 $(3.2)$(2.2)$(2.5)$(4.7)
Effective tax rate, as reported66.7 %26.3 %125.0 %14.3 %16.1 %25.0 %
Effective tax rate, as adjusted26.8 %26.3 %26.9 %26.8 %27.2 %27.0 %



AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions except per share amounts)

Net Income (Loss)
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Continuing
Operations		Discontinued
Operations		TotalContinuing
Operations		Discontinued
Operations		Total
As reported$0.5 $(1.4)$(0.9)$(7.8)$7.3 $(0.5)
Acquisition and integration-related charges0.3 — 0.3 1.5 — 1.5 
Restructuring and transformation charges2.9 — 2.9 8.9 — 8.9 
Post-RH Divestiture transition charges1.0 — 1.0 — — — 
Post-RH Divestiture restructuring0.7 — 0.7 — — — 
EU MDR Compliance1.3 — 1.3 1.1 — 1.1 
Intangibles amortization6.1 — 6.1 5.8 0.5 6.3 
Tax effects of adjusting items(2.7)— (2.7)(3.5)(1.1)(4.6)
As adjusted non-GAAP$10.1 $(1.4)$8.7 $6.0 $6.7 $12.7 
Diluted earnings (loss) per share, as reported$0.01 $(0.03)$(0.02)$(0.17)$0.16 $(0.01)
Diluted earnings (loss) per share, as adjusted$0.22 $(0.03)$0.19 $0.13 $0.14 $0.27 


AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions except per share amounts)


Selling, General and Administrative Expenses
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Continuing
Operations		Discontinued
Operations		TotalContinuing
Operations		Discontinued
Operations		Total
As reported$83.6 $— $83.6 $88.8 $3.9 $92.7 
Acquisition and integration-related charges(0.3)— (0.3)(0.2)— (0.2)
Restructuring and transformation charges(2.1)— (2.1)(8.9)— (8.9)
Post-RH Divestiture transition charges(0.4)— (0.4)— — — 
Post-RH Divestiture restructuring(0.7)— (0.7)— — — 
EU MDR Compliance(1.3)— (1.3)(1.1)— (1.1)
Intangibles amortization(2.7)— (2.7)(2.2)(0.5)(2.7)
As adjusted non-GAAP$76.1 $— $76.1 $76.4 $3.4 $79.8 
SG&A as a percentage of revenue, as reported
50.3 %— %45.7 %55.7 %12.0 %48.4 %
SG&A as a percentage of revenue, as adjusted
45.8 %— %41.6 %48.0 %10.5 %41.6 %





AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)

EBITDA
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
Continuing
Operations		Discontinued
Operations		TotalContinuing
Operations		Discontinued
Operations		Total
Net income (loss)$0.5 $(1.4)$(0.9)$(7.8)$7.3 $(0.5)
Interest expense, net2.5 — 2.5 3.0 — 3.0 
Income tax (provision) benefit1.0 (0.5)0.5 (1.3)1.4 0.1 
Depreciation5.3 — 5.3 4.9 0.9 5.8 
Amortization6.1 — 6.1 5.8 0.5 6.3 
EBITDA15.4 (1.9)13.5 4.6 10.1 14.7 
Acquisition and integration-related charges0.3 — 0.3 1.5 — 1.5 
Restructuring and transformation charges2.9 — 2.9 8.9 — 8.9 
Post-RH Divestiture transition charges1.0 — 1.0 — — — 
Post-RH Divestiture restructuring0.7 — 0.7 — — — 
EU MDR Compliance1.3 — 1.3 1.1 — 1.1 
Adjusted EBITDA$21.6 $(1.9)$19.7 $16.1 $10.1 $26.2 



AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions except per share amounts)



Free Cash Flow
Three Months Ended March 31,
20242023
Cash used in operating activities$(8.0)$(6.8)
Capital expenditures(4.1)(4.0)
Free Cash Flow$(12.1)$(10.8)


2024 OUTLOOK
Estimated Range
Diluted earnings per share (GAAP)$0.63 to$0.87 
Intangibles amortization0.37 to0.34 
Restructuring and transformation charges0.08 to0.06 
Post RH-Divestiture transition charges0.12 to0.10 
Other0.10 to0.08 
Adjusted diluted earnings per share (non-GAAP)$1.30 to$1.45 



AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)
March 31,
2024		December 31,
2023
ASSETS
Current Assets
Cash and cash equivalents$75.8 $87.7 
Accounts receivable, net131.3 142.8 
Inventories165.6 163.2 
Prepaid and other current assets28.6 28.8 
Assets held for sale66.5 64.5 
Total Current Assets467.8 487.0 
Property, Plant and Equipment, net116.2 117.2 
Operating Lease Right-of-Use Assets24.2 26.8 
Goodwill794.9 796.1 
Other Intangible Assets, net232.8 239.5 
Deferred Tax Assets6.3 6.5 
Other Assets19.1 19.3 
TOTAL ASSETS$1,661.3 $1,692.4 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Current portion of long-term debt$9.4 $8.6 
Current portion of operating lease liabilities11.5 12.8 
Trade accounts payable57.0 56.3 
Accrued expenses75.1 93.2 
Liabilities held for sale52.2 63.7 
Total Current Liabilities205.2 234.6 
Long-Term Debt167.2 159.4 
Operating Lease Liabilities26.6 28.3 
Deferred Tax Liabilities23.6 23.8 
Other Long-Term Liabilities10.8 10.0 
TOTAL LIABILITIES433.4 456.1 
Stockholders’ Equity1,227.9 1,236.3 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$1,661.3 $1,692.4 



AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS
(unaudited)
(in millions)
Three Months Ended March 31,
20242023
Operating Activities
Net loss$(0.9)$(0.5)
Depreciation and amortization11.4 12.1 
Loss on asset dispositions0.3 — 
Changes in operating assets and liabilities, net of acquisition(22.0)(19.3)
Deferred income taxes and other3.2 0.9 
Cash Used in Operating Activities(8.0)(6.8)
Investing Activities
Capital expenditures(4.1)(4.0)
Proceeds from RH Divestiture post-closing settlement2.1 — 
Cash Used in Investing Activities(2.0)(4.0)
Financing Activities
Secured debt repayments(1.6)(1.6)
Revolving credit facility proceeds20.0 — 
Revolving credit facility repayments(10.0)(20.0)
Purchase of treasury stock(9.1)(1.1)
Proceeds from the exercise of stock options0.5 0.6 
Payment of contingent consideration liabilities(0.5)— 
Cash Used in Financing Activities(0.7)(22.1)
Effect of Exchange Rate Changes on Cash and Cash Equivalents(1.2)0.9 
Decrease in Cash and Cash Equivalents(11.9)(32.0)
Cash and Cash Equivalents - Beginning of Period87.7 127.7 
Cash and Cash Equivalents - End of Period$75.8 $95.7 



AVANOS MEDICAL, INC.
SELECTED BUSINESS AND PRODUCTS DATA
(unaudited)
(in millions)
Three Months Ended March 31,
20242023Change
Digestive Health$94.7 $88.8 6.6 %
Pain Management and Recovery:
Surgical pain and recovery$31.2 $34.7 (10.1)%
Interventional pain40.2 35.8 12.3 %
Total Pain Management and Recovery71.4 70.5 1.3 %
Total Net Sales$166.1 $159.3 4.3 %
TotalVolumePricing/MixCurrency
Other(a)
Net sales - percentage change4.3 %5.2 %(1.1)%0.1 %0.1 %
______________________________
(a) Other includes rounding.

 EX-101.SCH 3 avns-20240502.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avns-20240502_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover [Abstract] Written Communications Written Communications Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 avns-20240502_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 avanoslogo.jpg GRAPHIC begin 644 avanoslogo.jpg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end GRAPHIC 7 avns-20240502_g1.jpg GRAPHIC begin 644 avns-20240502_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_[@ .061O8F4 9 !_^$ AD5X:68 M $U- "H ( (!#@ " '0 ": 00!V &$ ;@!O ', 7P!L &\ 9P!O M %\ 8@!L &$ 8P!K #< 7P!2 $< 0@!? #0 , P ' > /_L !%$=6-K M>0 ! 0 !? #_X06&:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \ M/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z M:V,Y9"(_/@T*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O7!E+U)E M&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA M<"\Q+C O(B!X;7!-33I/&UP34TZ1&5R:79E9$9R M;VT@&UP+FEI9#HS838S,38V9"TX-S!E+30Y M8S,M.#DT,BUD-V1D9&-A-F1F9&$B('-T4F5F.F1O8W5M96YT240](GAM<"YD M:60Z,V$V,S$V-F0M.#"UD M969A=6QT(CY!=F%N;W-?;&]G;U]B;&%C:S=?4D="7S0P,'!X/"]R9&8Z;&D^ M/"]R9&8Z06QT/@T*"0D)/"]D8SIT:71L93X\+W)D9CI$97-C"UD969A=6QT(CY!=F%N;W-?;&]G M;U]B;&%C:S=?4D="7S0P,'!X/"]R9&8Z;&D^/"]R9&8Z06QT/@T*"0D)/"]D M8SID97-C&UP;65T83X-"CP_>'!A8VME="!E;F0])W2SENC[!^RWUF]NJDU5=G!7 M'*=W#N5JJJK&YG9O ZRRJYP3LI44P.L83"!2$1*0A0$?FE* > :@_I M;[*NB^B;;L,]UOD1D+F0M@'E-G&XY2K^:J?(1N/5[U+IO/ZNY(JP'D6Z;=0Y M2"0)./([0,F7Q.J"/R>+L=&W#%Z424H=@U63AH - "&7>1Y5]Q3A;SPRGCVF M\M,W0.*[J6/ROBB-;682Q\74KEY@JQS2(0 M$P AV\M\.F901V*F=01\-&>KGRSM\U'@L!=6DH: #0!I1W%.433AQPSSOGT7 M*"$_5J57 M^6KV[8XS9WB7&1;P-%H?FL5'35,4TQ2/)RQW95!\0,1%(P>T=Z\):ED^L)PB M>#3A8: (\.ZERR/PPX-YLS+$R 1U[6A"T+%JP;^>3(MYZF3!='8I@ZXY,RS\ M.H.G^!'?PUC2W12;I7LROT#NV=RH/#_;/SE_RVG?_P +4/\ 2WV4]%]#%/IX M>YSG'.V;,L\;N3N7;/E*:M55;Y!Q1-760&0E&+^I&\F8BT%C&*4".&;A)T1( MI-]T5#;^(Z?AH[.&*UHDI0WCJH0&@ T &@"#CU >?#L-?\ !62;3BVY MK9NH\$M8ZB_^CI16&?,Y519L93I,/EJ'1(8P>_8-)W;JO S)2_(EQ']WGN6Q MT@PD4^9.:'"D>^:/TV[ZP$>L'"C-0JA4UT%$1373.)=E$S@)3%W*8! 1#4G] M;?91T7T/[=L3N"TCN(\;(7*425E"9-K LZOFJA(+=2E4NR:6_GH%$PJ"QEB$ M,X8J&^UZDQ$5$C[6YW[J2:]>C)&-,,!H TI[CM[N.,."7*S(6/K%)U&[4_"] MQGJQ9H9?X:5A)ABAU).$%-AZ#IF\0';6;^$S5/+17>?_ -;>Y5_;/SE^%/\ MY6H/Z6^RKHOH>9[%^:/?":2G,38HCVG M(/D/%F58RT!%2P-,=X[DB@("G.RJ(*'7'D9^S6"*&-XB)E5E#G$1_ M5'2YDU!F#%G*[DWA"1:2F(N0&8,>.62J:R256R%*1<IDSSCF2AZ=S1K+7.%",HV9NPUR+MBGP.:4V+J_F3!%[AL@4" MQIF!M*Q2HE:!P/OO[]]8-&Z. NY?SLXT2K.0Q1R;RFR8M%$! M&J6BR+7RD.44# 84CP\T+Y@0IP#I,9),I]O88!V$-UT=>&<=$_@QG> MX':G. \N8<>5W,\!4WMJ8KFH6(%%)9600<*J.J^NJLL0B1!5625, M.Q3ICTD&K+7OX9/IGU\C"^GB@T *%>J2Y9 PKN$N&-:DT_B)]T;-N4&S=4AU M$XR+,O'UQHMT'ZR LY%ZY.D=H+&;G3E:VZ2=I )R^(%.9+I-\H"(:ZG'DXU);&8 S) M6.0V$<4YQIJQ5JUE6AUJ[Q8!U=34D\U364;' Y2F [58QT5 $ $#%$->E5]E M)$U#@R]KIP- "O\ ZGOBP.0^-.,^4CG;LDR*ZZN#>+6S(: $T?5*\KOC)G!O M#2MR8"A#HK9NR@V;N"F*:3?E7C:XT6* =1#(-OCG)BF'8P*I&VW*&I?8M\%& M-?D4YQCCVRY;R-0\74UBM)6O(EOKM*KK%N@=PJXF+*[29H!T$ 3" **@)M@\ M W'4R4^!S<%LEQ[PS6N.^#<38,J")$:[BJ@UFDQXD,;&<1.0D M]Q3Y,X3Y#5P53/<67Z%L+UFB8"'EZV8PMI=AU" @4)"*7<-A';P ^^M5MU0UO5 =*E,X1*!A!(KMD(?$,5C?8*EV$?+.H!MYWZ. M3%Z]E!9UX>RYC_/6,*/F/%EA:VG'^1*^QLM7FV@_,=1[T/$BA/LD5FZ@&171 M-\Y-0IB& #%$->@GV4HD:@R3KIPC][K'Z.#FA^0"^?$A\E6 M$8[CSA&923>1%WR!&KN[/;HY4-R.(2OIF0<.4% V$CETL@D8!ZDC*AOIU,7< M5;55)[:QZ6+B)'QOE6S/V?[)+&1*4[Z+"!K3 B^WB=-L:-?*% 1\0*=1A[+-,VZJR-$S7"HQ!I=0@@()H3T27R43F+N! M068 41VZE"!N(9MZWTS2V^Q5_.>!,P\:6NW3G%A?*DY? M6'%EE=Q\?F3%"CT4HB[5I(X@*Z!3;I-I)@0YSLG6VX#NF?J2.)1U>GV4HD:@R3KIPPOR-S#&\?,!YESC+I%<,,3XTN5]5:G*8Y'BE98+ND MD! ABF$%E4RD'I$!\?#7+/JI.I2X*G?*63+IF;(]WROD6:=6&\Y#LTO;;1,N MU3JJO9>:6,LJ(=9CF*0@FZ$B;[%(!2AX &O-;GR6I02.=L#M09@[EEMLRE?L MD;C'#N/',-4FE22+]K-R=I\<;SG]'1@OZOYCC61A*7S&S%-9=G M.@GN(J V.FMM]@@<-Q!5\'7CR;KJGR,X=G[MQ07;VXT1T5/,H]YR!RHC&VS- MEE0 %E&C\R74RKK5;;?X6#35,0>GP47,LK]B8@%HRSZ+_HG2W9DL^FF#JOWS M2,8O)*0<)-&$>U MOP%1$P^'MUEGWDSI?K!"],1$E 2TI S3)>-F(21>Q$M'.B]#EA)1JID5T5 \ M=C)*D,4P?*&E#!Y7TPG*X,A<<,E<4[')D5LF!K*-NI#993_&7&,O:5!-M6'(T-J@2&@#"O(["=;Y(8&RY@BW)HF@ M/>>4Y3\?LB!KEEV4'4XR4C;5C^VV*E62/5+TJ,YVKNUF3M,0_Z"Z!@UYK4>"U.1L/TM?*T["RY MPX:V*45%I/,BYNQHT<+JJ(I2L4#>-L+9 H[I)BNV,R<=(;"/EJ&\=AU1Z]O@ M3M7Y'.=5DYYDU,1M>AY:?F7:,?#P<8_F)5^X.";=E&QB1UEUCF'P*5-(AC&' MY T 53'.CDM*\O>6F.O-O;LY+:KJH);O3:<6"YLYO2&;9Z-(\IO&"IJ6M$[EOYS57)- MP\Z.@4]QV IVZ)7KY,P>PZ!/ETWUZRY^C&MH4%@9JTE#0!\?D*]5O%]#NF2; MB^"-J=!JL_8<_6]0YIW*U^L%N60,H94D9'OUC Q8)"<1-Y4>Q(BV2 ?80A0]VO-L^S MDM2ZJ"4[MO\ :Y?Q^1N/)7\:B*C(&2\6WW#]F+ M4,C5N0K$\M!UZS,VC]/8DC6[8S1D(U^V4*(D70>LUR*I*$$0$!V]H" =:@XG M)/\ =@?NG_[*F4$.*F;IXZ7'G,=@2+4YV3=]+#$64)4Q4DW!C*#THQTV?I1> M>PJ:OEK_ #2^>)G8Z=?#X%:T[>4/V@(" " @(" " @.X" ZM)B/[NL?HX.:' MY +Y]S#K&G#-4Y15JZ\XM+%WTY_Z+?%?Y1,R?S^[U=A^237]$Y^G"S#/(K-% M?XZ8(R[G6T_.@L48^L]X>H>/4^- M5%D6Q>G!2%*4 M/ ->:W+DM2CP3Y^GW[8=3&?#9*RL5--V1! MXF8/+<,H1NHBX6*UOU\(?L333133223(DDD0J:2 M290(FFF0-BE*4-@ -@ -6DQ^] !H C#[I_;AQWW#^/Q,W"KJ-G;98NX])T%TCD.&_@(#KS^"L< M:]+ER^D)6'S'PHM4F*Z-70-FG$B"ZG4HUB)%RDSLK%(.@.E--\X9NR )A^^KU[? C:OR-\ZJ$&D/;,[)%56RRL_'QT6ZA'C]4Q6[!P08Q!1F9,';ZR1&0TH5AD+D <,(TTJ3@$I!"/LR2AI]ZD4!!39O")KI H0=R M**I&^32MK=:C,ZRRMSU 5EEUV1.*0<4NWSB*+EXPL??LOMC9NR!UHE2>!(WM M)%2-;+"4Y^HS*$39HB&_@8#> #OJ_&O6I'I;LQ/_ +_O$\O&?N W:R0,9\!0 M.1<>GFBL^0B1)BWG9A4Z%A:D!)--,@IS"*KCRP\2D63$?:&\V]>MBC*THP-V M=>5JG$3GWA.]2$DHPHMWEPQ%DH@K*)LU*CD(Z30JZY2& #EC9'X5Z'5X *6^ MLY6ZV.Z5[(LZ]>@1AH - %?%ZD'BT&$.=(9C@X\&M.Y.51K=C*)%Z6Z60ZR" M<9.I 4J92$%9,C-X;YPB8ZQS#^K%O6'/V59.41,<(^1\OQ)Y7X+Y"11U13QU M?8E_86B0_.E*7)"9C.--A$"B+F)T0 M<+9J](-I> L43'3L'+,E/-9R AKTN2(A3]0+RK+ MQN[?=VJ4+)IL[]R0D$\,5U$BG2\)6)1,R]E=D+X")"1"9F@F =RG<)B&D[VZ MU&95EE M4%D"NNT$E$_C$\8TT[=_-J 4Y#& CER9DS,8NP]*I@W]ND;VA0-RK+D0 006 MVCQ9:Y&N@?2,OYIB^"WPJZ_P9#C[4TB?)KTN*A>('/C.&-XF/+'46T37UK8T12(5-LC2)MD2D "D3C7WQ+$ MA?[E(-_;J+6O6Q5F^R-EO3[_:Z;<[^VOQ;RIBR%!3E)A/C%BM>FE:% KK)M)1@& M3AW5U_9YJP'ZEXLQA^:L)T@V*X.8++Y]ZI_)-6_5L1$=M'3!TY8OFSAD]9.% MFCQF[1,W=-'342O\ =8_1P*(7$/;.XG0\.@5)2WXV9Y5FUNG99Y.91 M54FE3J#L!C"FF\31+O["D*4/ #7H9**HCTL;1 21$DS_*!'R;=4 ^4@:,7% MD&BFI97ZO)#C52272507236063.DLBJ0%$E4E $#%,40$# 8!V$!T 5]'>;[ M-F1^(^1[IR#P14I*V\4;?+O;(X)7F:LD^P8_E53*KQTFB3S%21A%CC\$^'YA M2"5%8Q3@4RL6N3KY7!5GIV\/D7NT@:2+<2NZSSEX8J1[#$>:YV1HK$R91Q9D M,QKUCP[4G0 HH,GIS*QA1*0 W8*HF_5UNNCIPS%J*PUGP>]2IQTS<^AZ%RPJ MY>-5Z?BBS1OC5\I/X5E7R@](>>Y.7Z1KX',(;?%%51* "*CDH:II["?(FV37 M RK&2<;-1S"8AY!C+1,HS;2$9*1CM-_'2+!X0%$5T%TC'26353,!B'(80$! M0';5 D[V@"OX]25RO/FSFLQP/!2BKFD\8*V2MN6J2RGP*N3+@1"0FEN@1\LQ MV[8&30Q@#P,DU9&41 M0*TQQ2?Y2E^L_28J7Q3=O\(D8P;>8J0OM$-+SKV:1J]NJDM,V[=!H@BU:HHM MFS9%-NW;MTP10;H(@!2$(0H 4A2% #8 UZ)&+\^H[XH#GC@R.9(",%Y>. M+EB"^$40(47:V-[%Y+"QH[F,79- H-9!3;<>EL.WM'=&]>RGZ&Y6AE>_J(J+ M0#M%\K2\PN!6#\F2,@1_>:["?5;DW%C#/[QQLF6N7X46Z:BSU2JHE M^"L:!"I^ E+&K?&*=0; #??VZ3O7M49E:&5TNH2LL8O3ZH] MY5J9SYS&PS"22CBD<8*XE1RMDEE/@E<= F%,5$@,U9&,4/\ L!#Y M=(WM+@=E6$1*<*N.DMRSY58,X]Q*3@Y,I[,PO)IZ;H$# 5 MG%-W"QA ?#ITJE>S@W9]5):Z0,%$5>"A:U ,$(N!KL3'04)&-@$&T=$1")&[ M9!/J$1Z444RD+N/L#7I<$1ZV@ T 5MW?BY8&Y0]P;)3"%E!?X]P$0N#Z65!W M\1&KO*JLJ:>?(]!C(F^+G%7!"JD'YZ220^X-0;6[6*\ZPCYKL?\ %(W*ON#X MC8RT6K(4'#;D N1]V^I_8K*D=B_,".\+,25=F8FP0KQ>/F(*383$2_;*"DY8R48 MJ1=!9,Q1 Q3)*D*8H@/@(:C*"UEX*&;;H5:UR9RI(VM)$@;)MI9L+Y%IF5\9V*0J=^Q_88VT56P1BHI.HZ6BU .0?#P434 M !352. E4()B' 2F$!G3CR.:D?=LODF'4=1$IA\T6,H4IG#%0WM+U)B(J)*;6]^]6R;KTLBOEU"5%B[Z<_\ M1;XK_*)F3^?W>KL/R2:_HG/TX603>HUISJT=L/(,JT167-1,EXHMK@B*9E#% M9*2A8I4X@4!V*F$F!S"/@ (CX:3NO\ R,R?DKK-0E99_P#9WR3#Y1[:'$"; MAW)7)8#$D/CJ3 !W.A-XS.K NR'#V@/FL!-X^T! ?8(:]#)S5$>BALDMTPP& M@ T &@"N4]0]D>&R!W/,I,85?XDF-J3C;'$DH!1 A9F-CPD'*8#[#>4I)^6( MA[P$/: AJ'=S8JR4(Q!V.::]NO=(XHM&:)E"0-HM%R>J 03$;,JE 2KT3G'V M% 3I%( C]L8 ]^N8J;([I^6696KR0- '"X;H.T%VKI!%RUP8G;HEI+^ M15ZS>8^JZW3'& RA^H_P)VIS#]D<=)O@K?\ !E=7458YI]A;G'Q#CYBZ0]>C M^0^)XDJKIW=L1(+O9V'CDP,85Y2N*E&4:E(F03*J-@<(IAXF5 /'4U\;5'5U M5B$X0$!$!#80\! ? 0$-*&C/OI[>Z+<<3YCJ_"+,=F=S6%LKOAA<1/)R0\PV M+JC#2'#$ZTE2.<\GL[5KC'QZS% MGZVJIDA,54&?MAT%%01&4DV2(ECV!#" @"DC('0:I;_;G+JJUNJDG2EP5.U^ MN]CR9>KED:X/AD[9?;3/W*RR EZ/C9ZS.E7CM4"[CT@==8P@7?P#PUYS*(PU(S;S(L<6!'MS?DPQC-XX3(*@5JOG1?3[E P'$X$=R/PK<>HH?. M;&VU5Z]?D1M;X&X=4B#Y>[TZOY#IMKH-L8)2E7NM+?([,O'^SD5^DL77V>K*#M4ABA+0C=83 MQSX@G(F)B/H\Z*Y3 4 $#>'AKSK5ZN"VKE2,,>E]Y7#1L]Y5XEV*1.2 S77@ MOM$;K*"*#?(M!3-\8BF!C@4@R,()9 MJY"W&MV"HV6/;RU=M,)+5R?BG9/,:R<+.(*-73=4OVQ%D%3$,'R#HY#@J?N7 M_'Z9XK;: MO5P6U?922 ]F#N(17;\S5F"9'PC<6SF.22%7XO)-%:.9:K%\ -TB\ M=%7CBCML!G)1,(%*(ZWE?HS.E.Q$K=[C/Y$N=NO]K>C(VB\6:>M]DD!+T"^G MK(Z5>.UMO';S'"QS;>[?2VY-KP-7>EKXM%GO+$[/X'5]5DX: -).XQRC9\..& M6=L\&=)M[#7::]A\?I'4\L[S(]J_DZ$(7^#5W\M\X(LL*2;:TN!EC5 DPQR*PI5^1V"_<$UI'L?D;CR5_&HBHME^&7^Z'Q=_-\P]_H_'Z]*G"(;JQ8:5<82.LE3MD+)URRU^7;%>1VQ9>W=R*=Q,,TE)/CWDY>2L6$K@Z 7)4F!% ,[KSU?;87L(*I"" M)O%5$R2H>)CE)Y^N?1_\*\[]D:*83Y&9/P&RRU#4*8\BN9PQ99L0Y,K;SJ7A MK)5+&D(%,HB!@*#A@OTKM%P^<0W4 #TG.4V:V=3;4F"=9.EB[Z<_]%OBO\HF M9/Y_=ZNP_))K^B<_3A9@+E/@R)Y,<<HG0>W/DL2@:O]+=Q0DY"\9KY MEV*+61@:]!CA3&CQPB02P0*DZO5TYN(/9FT4WG7-=))(FG6\([5402>': ?X@B"J MZ*B9%1)TB8IB@.X"&@#U] !H 0#]25Q/Q7Q[Y9X^R5BN&C*HWY%TV?MERJD, MV(RBT+S6GR;=[*(MT]B(?2R;M(ZI2% IE2**;=1S#J+>JJY15E:40 8ZM,K1 ML@T6ZP2RK:;I]RK%IAG"!A(LA*U]Z@[;G((>(&*LB40$/?I"<#.1TKU0_+ U M0PUB/B'6Y$R,QEJ<')N0DFZAB*%HE+.9&,:J]"@ )'\P<5NDY1\6H"&J_8M" M@GQK\B0FI"D<1X@>H7X2<2.,^&>.]7X[;G"..5LMY@E^:DETA]D.D:W5W*&YU=5# M-$>..;;+QNSUB+/%044+/XIOU-C@8-@' M=)8-_P!77I)R1-0?=:Z<#0 DGZH_BT:M9;PMRY@& %BLEP"V*;\NB4VR5OI@ M&U;Q>#B%P1P%B)\S*RMRE41OF0R=)RK? MU]R!M)OTE04*0X&9>>1IL(> ) > !KT8_+6X72O7HK$'RM]BVX,G;UN+!Z]1 M\IXV;MSF 3%'S.LVWSM3Z65W*'43JH9\#V^^3;[A]S%P-G]!9P2(IEX8-[JU M;J@D,ECZQ@:-G&X]7S!$T8Z6,GU ( <"F]I0T4MT_<$UI'L?D;CR5_&HBHME^&7^Z'Q=_-\P]_H_'Z]*G"(;BNH9JMNKDK .2''C*'%3-5]P-F&!5@;SC^:7BWQ-A/'S# ?GLY-@J M( #AI(MC$7;JA[2&#< ,!BAYUJ]7#+$^WDP?KATL7?3G_HM\5_E$S)_/[O5V M'Y)-?T3GZ<+#0 GKZB3M4S4W(2_< X_UL\DS^#6,'ZNGK>HK^5C4?DEZGSB;1X M-ZTXTX\R!G.YJME C)"SQQL:8^8N1$"E.Y4=>9,. * B;RDV9.K;I\PF^X8M M["7!I8M\B?/,?FYR&YV925RKR"N1YV0:HK,*I58I(T71Z%"K& PLH:.ZU"-B M'$I155.8ZJH@!E5#B "$M[N[ECZU5> X5<,LQ\Z\[UC!F'8@ZSR262?6^W.V MZAJUCJFHJ$*\F)18@"!$T"FV23 >M902I)@)S!HI1W<(+6ZJ2SWXM<;<<<1L M"XXX^8JCP9U''<$E&INU$2)2-AF5S&6D)5Z) V.YDWJBCA8?8 FZ2[% H!Z% M:]5"(V^SDV UHX1I]SON48Q[;V$2W2PMDK;EJ\%E8G"^,"JF1-:9Z/(F*SQ^ MJ3YS6-BQ72.[5 >HW45)/YYP$J]-/YHW2G=E>VS[BW,..Y92/-=CF6P-L_2T MFHYDI\@E/!O8%02@$ K%'ZF*D0FBF1%./,04RE*42@"A2G"+^CF?DJZ*(&KN M*7J@\!VR$C87EYC&U8FN:#4JS2"[ZHSAW4[_FOF7SGSCF&/Q?E)]26M@-C[&!BT*4.W#'E"$[!BLB(,B#T2 M*A%G^Q@W 5A ?'7=6[6;.475$>'U'YJ_%!E'\ );[TUB#G.SK>+OPODL!Y/KUN@+=QMM2D%!&MD$[AE M)/&=T%>1B@0,[(F9?Z/=E>MC%*&R:94 ^V#5N%I4$VJ\C!6G"@T 1N=VSBN/ M+_@3G;%T9'#)7>$KXY.QFBDF99V>^8\ []LW;E*("962:E<,"[^'\/XZ7K7M M5HW1]65HWU'YI'Q#$&4!_P#H$M]Z:@AEQ^1N7(A M:.$,T@ B.("+NO8\M\HLO*V' 4\J$1CZ:?JB8ZJM<>E*8D&HL8=P9+%^&W$> MA1N0 (,VF$^:CJ:QX8H?GGBGR0XP3RUK)\&O^N&CTX:%F;%)LX2OQ,G.S,BL5O'Q$ M,P5DY-\X/[$T6Z!#JJF'W%*41T'"<#A#V ^:W*F2A[#D^N.N,6'EU&KE]:LF M1AT+U*1IS%%0L36#'2D#*BF/S3O_ (=+W@8PATZ=3!VY\"[:JH\MPKX,8$C^]9$G4"B4'DN^!-,5/+ Q@0;IE*BB B"1"]1A- M92BHO!/:SMR;AZT9#0!K7RHXCX#YG8LD\0\@J*QN-8>>8XBGY1^!M%0F>@Q$ MY&&D2%%=@Y1W\#%W*<-R*D.F)B#FU%?PSM;.O D!SG].QRUXYR$W;>.C9UR@ MQ B*[QJG76I&V8(!@7K/Y3Z"*(?29DB% /.C1.)Q\?(2WZ=27P=>/)375/D@ M$LU5L]+FGM;N-6W-BRLH+ 6(+'/PZS@$I/(LRT4KN,*ZB4W2HH]G')"L]TPW'R$146 M-L($2./AK=:._!FUE7DL#NUOVM\6]MK%KZ.CGS:^YQOS:/4ROE51A\+\:+,. MM.(ATS[JM(UFJ8QBE,/6L?\ A5=A!--*W/-9HEO?N29I_P 6G^T+^QIA@_>@ M T &@ T &@ T T &@# MA#K-N#M>2M4Y0?ZY)K_+UO\,74%N2Q<#8785_^ M->?Y(T_?AJC 1H-":I$AH - !H - !H 7;[ZO^KIO_DC_P#>IZ1J,S%!.)'^ E\# _Y\;?X74M.2E\%F'@G_5/2?\ ,;#_ 1->@B-\F7-=.'_V0$! end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page Cover Page
May 02, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 02, 2024
Entity File Number 001-36440
Entity Registrant Name AVANOS MEDICAL, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-4987888
Entity Address, Address Line One 5405 Windward Parkway
Entity Address, Address Line Two Suite 100 South
Entity Address, City or Town Alpharetta,
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30004
City Area Code 844
Local Phone Number 428-2667
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock - $0.01 Par Value
Trading Symbol AVNS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001606498
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Cover Page Sheet http://www.avanos.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentPeriodEndDate - avns-20240502.htm 4 avns-20240502.htm avns-20240502.xsd avns-20240502_lab.xml avns-20240502_pre.xml avns-20240502_g1.jpg http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "avns-20240502.htm": { "nsprefix": "avns", "nsuri": "http://www.avanos.com/20240502", "dts": { "inline": { "local": [ "avns-20240502.htm" ] }, "schema": { "local": [ "avns-20240502.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "avns-20240502_lab.xml" ] }, "presentationLink": { "local": [ "avns-20240502_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://www.avanos.com/role/CoverPageCoverPage", "longName": "0000001 - Document - Cover Page Cover Page", "shortName": "Cover Page Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "avns-20240502.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "avns-20240502.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.avanos.com/role/CoverPageCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001606498-24-000055-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001606498-24-000055-xbrl.zip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avns-20240502_htm.xml IDEA: XBRL DOCUMENT 0001606498 2024-05-02 2024-05-02 0001606498 false 2024-05-02 8-K AVANOS MEDICAL, INC. DE 001-36440 46-4987888 5405 Windward Parkway Suite 100 South Alpharetta, GA 30004 844 428-2667 false false false false Common Stock - $0.01 Par Value AVNS NYSE false